Foghorn Therapeutics, Inc. (FHTX) News
Filter FHTX News Items
FHTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FHTX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest FHTX News From Around the Web
Below are the latest news stories about FOGHORN THERAPEUTICS INC that investors may wish to consider to help them evaluate FHTX as an investment opportunity.
Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should KnowFoghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
Foghorn Therapeutics price target lowered to $13 from $20 at H.C. WainwrightH.C. Wainwright lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $13 from $20 and keeps a Buy rating on the shares after the company announced the discontinuation of its independent development of FHD-286 in combination with decitabine for patients with relapsed and/or refractory acute myeloid leukemia. The firm is still believers in the BAF targeting thesis and sees Foghorns FHD-909 “as being able to still de-risk the strategy.” Published first on TheFly – the ultimate source f |
Foghorn Therapeutics Advances Precision Oncology PipelineFoghorn Therapeutics ( (FHTX) ) has provided an announcement. Foghorn Therapeutics has unveiled its strategic roadmap, emphasizing the advancement of its precision therapeutics pipeline, with a particular focus on oncology. The company is progressing multiple high-value assets into the clinic, including selective inhibitors and degraders for challenging targets like SMARCA2, EP300, and ARID1B, aiming to deliver first-in-class therapies with broad applications and potential blockbuster status. Mo |
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic PrioritiesObjective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy threshold not achieved to support continued development by Foghorn alone Company to prioritize investment into proprietary pipeline and Lilly collaboration programs, including the clinical-stage selective SMARCA2 (BRM) inhibitor, FHD-909 (LY4050784) As of September 30, 2024, the Company had $267.4 |
After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX)The heavy selling pressure might have exhausted for Foghorn Therapeutics (FHTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's WhyFoghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High?The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 104.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Foghorn Therapeutics to Participate in Three Upcoming Investor ConferencesCAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies London Healthcare Conference, the 7th Annual Evercore HealthCONx Conference, and the Citi Global Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and re |
Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter ReportFoghorn Therapeutics Inc. ( NASDAQ:FHTX ) just released its quarterly report and things are looking bullish. The... |
We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |